212 related articles for article (PubMed ID: 1000510)
21. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
Matherly LH; Barlowe CK; Goldman ID
Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of DNA synthesis and enhancement of the uptake and action of methotrexate by low-power-density microwave radiation in L1210 leukemia cells.
Chang BK; Huang AT; Joines WT
Cancer Res; 1980 Apr; 40(4):1002-5. PubMed ID: 7357530
[TBL] [Abstract][Full Text] [Related]
23. Studies on the in vivo synthesis of methotrexate polyglutamates and their efflux properties in normal, proliferative, and neoplastic mouse tissues.
Poser RG; Sirotnak FM
Adv Exp Med Biol; 1983; 163():259-74. PubMed ID: 6193689
[TBL] [Abstract][Full Text] [Related]
24. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
Edelstein M; Vietti T; Valeriote F
Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity and preliminary drug disposition studies on chartreusin (NSC 5159).
McGovren JP; Neil GL; Crampton SL; Robinson MI; Douros JD
Cancer Res; 1977 Jun; 37(6):1666-72. PubMed ID: 870180
[TBL] [Abstract][Full Text] [Related]
26. Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.
Fry DW; Besserer JA; Boritzki TJ
Cancer Res; 1984 Aug; 44(8):3366-70. PubMed ID: 6547636
[TBL] [Abstract][Full Text] [Related]
27. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
Chu BC; Fan CC; Howell SB
J Natl Cancer Inst; 1981 Jan; 66(1):121-4. PubMed ID: 6935452
[TBL] [Abstract][Full Text] [Related]
28. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
29. Kinetic correlates of methotrexate transport and therapeutic responsiveness in murine tumors.
Sirotnak FM; Donsbach RC
Cancer Res; 1976 Mar; 36(3):1151-8. PubMed ID: 943237
[TBL] [Abstract][Full Text] [Related]
30. Relative biochemical aspects of low and high doses of methotrexate in mice.
Zaharko DS; Fung WP; Yang KH
Cancer Res; 1977 Jun; 37(6):1602-7. PubMed ID: 870175
[TBL] [Abstract][Full Text] [Related]
31. [Disruption of DNA synthesis and structure of mouse L1210 leukemia cells, sensitive and resistant to 1-methyl-1 nitrosourea and 1,3-bis(2-chloroethyl)-1-nitrosourea in vivo].
Kukushkina GV; Peretolchina NM; Minenkova EA; Verovskiĭ VN; Sof'ina ZP
Biokhimiia; 1984 Jul; 49(7):1189-98. PubMed ID: 6477985
[TBL] [Abstract][Full Text] [Related]
32. Comparison of in vivo and in vitro effects of continuous exposure of L1210 cells to 6-thioguanine.
Maybaum J; Morgans CW; Hink LA
Cancer Res; 1987 Jun; 47(12):3083-7. PubMed ID: 3581060
[TBL] [Abstract][Full Text] [Related]
33. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine.
Sirotnak FM; Moccio DM; Goutas LJ; Kelleher LE; Montgomery JA
Cancer Res; 1982 Mar; 42(3):924-8. PubMed ID: 7059991
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells.
Chello PL; Sirotnak FM; Dorick DM; Donsbach RC
Cancer Res; 1977 Dec; 37(12):4297-303. PubMed ID: 922722
[No Abstract] [Full Text] [Related]
35. Pharmacological and therapeutic properties of carrier bound methotrexate against tumor confined to a third space body compartment.
Chu BC; Howell SB
J Pharmacol Exp Ther; 1981 Nov; 219(2):389-93. PubMed ID: 6974776
[TBL] [Abstract][Full Text] [Related]
36. Role of membrance transport in the pharmacologic action of antifolates.
Sirotnak FM
Cancer Treat Rep; 1981; 65 Suppl 1():19-27. PubMed ID: 7326662
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of L-canavanine against L1210 murine leukemia.
Green MH; Brooks TL; Mendelsohn J; Howell SB
Cancer Res; 1980 Mar; 40(3):535-7. PubMed ID: 7471074
[TBL] [Abstract][Full Text] [Related]
38. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
[TBL] [Abstract][Full Text] [Related]
39. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
